In the Claims

1. (currently amended) A film-shaped or wafer-shaped pharmaceutical preparation for administering active substances, said preparation containing at least one matrix-forming polymer, said at least one matrix-forming polymer comprising ~~which has~~ at least one active substance and at least one gas-forming component dissolved or dispersed therein, wherein ~~characterized in that the~~ said at least one gas-forming component ~~consists of a~~ comprises at least one carbon dioxide-forming substance ~~or of a combination of such substances, and reduces~~ for reducing or completely ~~suppresses~~ suppressing an unpleasant taste sensation caused by [[the]] said at least one active substance.

2. (currently amended) The film ~~Film~~-shaped or wafer-shaped pharmaceutical preparation according to claim 1, ~~characterized in that~~ wherein said pharmaceutical preparation is suitable for the administration of said at least one active substance[[(s)]] via the oral mucosa.

3. (currently amended) The film ~~Film~~ -shaped or wafer-shaped pharmaceutical preparation according to claim 1, ~~or 2, characterized in that the~~ wherein said at least one carbon dioxide-forming substance ~~or at least one of the carbon dioxide-forming substances~~ is[[/are]] selected from the group consisting of sodium hydrogencarbonate, sodium carbonate, potassium carbonate and potassium hydrogen carbonate.

4. (currently amended) The film ~~Film~~ -shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein said preparation contains ~~any one of the preceding claims, characterized in that the~~ said at least one carbon dioxide-forming substance ~~is contained in the pharmaceutical preparation~~ in an amount of 2 to 50%-wt, ~~preferably 5 to 30% wt, and with particular preference 7 to 20% wt,~~ relative to the pharmaceutical preparation.

5. (currently amended) The film ~~Film~~ -shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein said preparation further comprises at least one additional substance selected from the group consisting of ~~any one of the preceding claims, characterized in that it contains~~ at least one permeation enhancer and[[/or]] at least one blood flow stimulator ~~substance stimulating the blood flow~~.

6. (currently amended) The film ~~Film~~ -shaped or wafer-shaped pharmaceutical preparation according to claim 5, wherein ~~characterized in that the~~ said at least one permeation enhancer is selected from the group consisting of saturated ~~or unsaturated~~ fatty acids, unsaturated fatty acids, hydrocarbons, straight-chain or branched fatty

alcohols, dimethyl sulfoxide, propylene glycol, decanol, dodecanol, 2-octyldodecanol, glycerol, isopropylidene glycerol, transcutol (= diethyleneglycol-monoethyl ether), DEET (= N,N-diethyl-m-tolueneamide), solketal, ethanol or other alcohols, menthol and other essential oils or components of essential oils, lauric acid diethanolamide, D-alpha-tocopherol and dexpanthenol.

7. (currently amended) The film ~~Film~~ -shaped or wafer-shaped pharmaceutical preparation according to claim 5, wherein said at least one blood flow stimulator ~~5, characterized in that the substance stimulating the blood flow~~ is selected from the group consisting of menthol, eucalyptol, ginkgo extract, geranium oil, camphor, spearmint oil, oil of juniper, and rosemary.

8. (currently amended) The film ~~Film~~ -shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein said preparation ~~any one of the preceding claims, characterized in that it~~ disintegrates within 15 minutes ~~min, preferably within 3 min, and particularly preferably within 60 seconds,~~ after introduction into an aqueous medium.

9. (currently amended) The film ~~Film~~ -shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein ~~any one of the preceding claims, characterized in that the~~ said at least one matrix-forming polymer[[(s)]] is [[/are]] selected from the group consisting of polyvinyl alcohol, cellulose derivatives, starch and starch derivatives, gelatine, polyvinyl pyrrolidone, gum arabic, pullulan, acrylates, polyethylene oxide, ~~and~~ copolymers of methyl vinyl ether and maleic acid anhydride~~, with the group of the cellulose derivatives preferably consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose and hydroxypropylethyl cellulose~~.

10. (currently amended) The film ~~Film~~ -shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein ~~any one of claims 1 to 7, characterized in that the~~ said at least one matrix-forming polymer[[(s)]] is [[/are]] selected from the group consisting of cellulose ether, ~~preferably ethyl cellulose, as well as~~ polyvinyl alcohol, polyurethane, polymethacrylate, polymethyl methacrylate[[,]] and derivatives and copolymerisates of each of said ~~the aforementioned~~ polymers.

11. (currently amended) The film ~~Film~~ -shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein ~~any one of the preceding claims, characterized in that the~~ said pharmaceutical preparation ~~contains~~ further comprises an auxiliary substance for imparting mucoadhesive properties to the preparation.

12. (currently amended) The film ~~Film~~ -shaped or wafer-shaped pharmaceutical preparation according to claim 11, wherein ~~characterized in that the~~ said auxiliary substance for imparting mucoadhesive properties to said preparation is at least one substance selected from the group consisting of polyacrylic acid, carboxymethyl cellulose, hydroxymethyl cellulose, methyl cellulose, tragacanth, alginic acid, gelatine and gum arabic~~, or a mixture thereof~~.

13. (currently amended) The film ~~Film~~ -shaped or wafer-shaped pharmaceutical preparation according to claim 11, wherein ~~characterized in that the~~ said pharmaceutical preparation [[has]] includes a bilayer or multilayer structure having at least one layer in contact with said oral mucosa, wherein said at least one layer ~~with only the layer or layers which is/are facing the oral mucosa, respectively which is/are~~ in contact with the oral mucosa~~, being rendered~~ is mucoadhesive, and at least one non-mucoadhesive layer.

14. (currently amended) The film ~~Film~~ -shaped or wafer-shaped pharmaceutical preparation according to claim 13, wherein ~~characterized in that the~~ said at least one non-mucoadhesive ~~layers have~~ layer has a lower permeability for ~~the~~ said at least one active substance~~, respectively the active substances~~.

15. (currently amended) The film ~~Film~~ -shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein said preparation ~~any of the preceding claims, characterized in that it~~ is flat-shaped~~, with the~~ having a density ~~thickness of this flat-shaped preparation preferably lying~~ between 0.3 g/cm³ and 1.7 g/cm³~~, with particular preference between 0.5 g/cm³ and 1.5 g/cm³, and most preferably between 0.7 g/cm³ and 1.3 g/cm³~~.

16. (currently amended) The film ~~Film~~ -shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein the total thickness of said preparation ~~any one of the preceding claims, characterized in that its total thickness~~ is 5 μm to 10 mm~~, preferably 30 μm to 2 mm, and with particular preference 0.1 mm to 1 mm~~.

17. (currently amended) The film ~~Film~~ -shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein ~~any one of the preceding claims, characterized in that it~~ said preparation has a shape selected from the group consisting of ~~has a~~ round, ~~or~~ ellipsoid, ~~or~~ oval ~~shape~~, ~~or a~~ triangular, quadrangular ~~or~~ polygonal ~~shape~~, and ~~or an~~ irregular rounded ~~shape~~.

18. (currently amended) The film ~~Film~~ -shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein ~~any one of the preceding claims,~~

~~characterized in that it~~ said preparation is present as a solidified foam[[,]] having a ~~the~~ density ~~of this solidified foams preferably being~~ between 0.01 g/cm³ and 0.8 g/cm³~~; with particular preference between 0.08 g/cm³ and 0.4 g/cm³, and with greatest preference between 0.1 g/cm³ and 0.3 g/cm³~~.

19. (currently amended) The film ~~Film~~ -shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein ~~any one of the preceding claims, characterized in that~~ the polymer portion of the matrix has a weight ~~amounts to~~ at least between 3%-wt. and ~~maximally~~ 98%-wt.~~, preferably 7 to 80% wt., with particular preference 20 to 50% wt., each value being~~ relative to the entire preparation.

20. (currently amended) The film ~~Film~~ -shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein ~~any one of the preceding claims, characterized in that it contains~~ said preparation further comprises at least one additional auxiliary substance~~, said auxiliary substance(s) being~~ selected from the group consisting of fillers, colourants, disintegrants, emulsifiers, plasticizers, sweeteners, preserving agents, stabilisers, antioxidants and flavouring agents.

21. (currently amended) The film ~~Film~~ -shaped or wafer-shaped pharmaceutical preparation according to claim 1, wherein said preparation further comprises ~~any one of the preceding claims, characterized in that it contains~~ at least one flavouring agent, ~~and/or~~ at least one sweetener, [[and/]] or at least one plasticizer.

22. (canceled)

23. (canceled)

24. (canceled)

25. (canceled)

26. (canceled)

27. (new) The film-shaped or wafer-shaped preparation according to claim 4 wherein said preparation contains said at least one carbon dioxide-forming substance in an amount of 5 to 30%-wt relative to the pharmaceutical preparation.

28. (new) The film-shaped or wafer-shaped preparation according to claim 4 wherein said preparation contains said at least one carbon dioxide-forming substance in an amount of 7 to 20%-wt relative to the pharmaceutical preparation.

29. (new) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 8, wherein said preparation disintegrates within 3 minutes after introduction into an aqueous medium.

30. (new) The film-shaped or wafer-shaped pharmaceutical preparation according to

claim 8, wherein said preparation disintegrates within 60 seconds after introduction into an aqueous medium.

31. (new) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 9, wherein said cellulose derivatives are selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose and hydroxypropylethyl cellulose.

32. (new) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 10, wherein said cellulose ether is ethyl cellulose.

33. (new) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 15, wherein said preparation has a thickness between 0.5 g/cm^3 and 1.5 g/cm^3.

34. (new) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 15, wherein said preparation has a thickness between 0.7 g/cm^3 and 1.3 g/cm^3.

35. (new) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 16, wherein the total thickness of said preparation is 30 μm to 2 mm.

36. (new) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 16, wherein the total thickness of said preparation is 0.1 mm to 1 mm.

37. (new) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 18, wherein said solidified foam has a density between 0.08 g/cm^3 and 0.4 g/cm^3.

38. (new) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 18, wherein said solidified foam has a density between 0.1 g/cm^3 and 0.3 g/cm^3.

39. (new) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 19, wherein the polymer portion of the matrix has a weight at least between 7 to 80%-wt. relative to the entire preparation.

40. (new) The film-shaped or wafer-shaped pharmaceutical preparation according to claim 19, wherein the polymer portion of the matrix has a weight at least between 20 to 50%-wt. relative to the entire preparation.

41. (new) A method for administering a pharmaceutical preparation containing an active substance having an unpleasant taste and reducing or suppressing the unpleasant taste of said orally administered pharmaceutically active substance comprising the steps of:

preparing a film-shaped or wafer-shaped mucoadhesive pharmaceutical preparation that is disintegratable in an aqueous media of a surface of an oral mucosa of a human or animal organism, comprising the steps of:

applying at least one matrix-forming polymer to said preparation, said at least one matrix-forming polymer comprising at least one active substance;

dissolving at least one gas-forming component within said at least one matrix-forming polymer, wherein said at least one gas-forming component comprises at least one carbon dioxide-forming substance for reducing or suppressing said bitter taste;

adding at least one additional substance to said preparation selected from the group consisting of at least one permeation enhancer and at least one blood flow stimulator;

adding at least one auxiliary substance to said preparation for imparting mucoadhesive properties to said preparation;

adding at least one additional auxiliary substance to said preparation selected from the group consisting of fillers, colourants, disintegrants, emulsifiers, plasticizers, sweeteners, preserving agents, stabilisers, antioxidants and flavouring agents; and

adding at least one flavouring agent, at least one sweetener or at least one plasticizer to said preparation; and

applying said preparation to said surface of said oral mucosa for disintegration in said aqueous media.